PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why Pharmascroll
  • Reports
    • Neuroscience
      • Migraine
        • Migraine- Disease overview
        • Migraine- Disease overview and Epidemiology
        • Migraine- Disease overview, Epidemiology and Drug overview
        • Migraine- A Detailed overview
        • Migraine- Detailed overview Acute Treatments
        • Migraine- Detailed overview Prophylactic Treatments
      • PPMS
        • PPMS- An Overview
        • PPMS- Disease Overview and Epidemiology
        • PPMS- Disease & Drug Overview and Epidemiology
        • PPMS- Detailed Overview
      • SPMS
        • SPMS- An overview
        • SPMS- Overview and Epidemiology
        • SPMS- Disease & Drug overview and Epidemiology
        • SPMS- Detailed overview
      • Alzheimer’s
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Parkinson’s
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Schizophrenia
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Depression
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • ADHD
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Epilepsy
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
    • Respiratory
      • Asthma
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • COPD
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • cystic Fibrosis
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Rhinitis
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Idiopathic Pulmonary Fibrosis
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
  • Research & Consulting Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why Pharmascroll
  • Reports
    • Neuroscience
      • Migraine
        • Migraine- Disease overview
        • Migraine- Disease overview and Epidemiology
        • Migraine- Disease overview, Epidemiology and Drug overview
        • Migraine- A Detailed overview
        • Migraine- Detailed overview Acute Treatments
        • Migraine- Detailed overview Prophylactic Treatments
      • PPMS
        • PPMS- An Overview
        • PPMS- Disease Overview and Epidemiology
        • PPMS- Disease & Drug Overview and Epidemiology
        • PPMS- Detailed Overview
      • SPMS
        • SPMS- An overview
        • SPMS- Overview and Epidemiology
        • SPMS- Disease & Drug overview and Epidemiology
        • SPMS- Detailed overview
      • Alzheimer’s
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Parkinson’s
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Schizophrenia
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Depression
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • ADHD
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Epilepsy
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
    • Respiratory
      • Asthma
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • COPD
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • cystic Fibrosis
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Rhinitis
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
      • Idiopathic Pulmonary Fibrosis
        • Disease Insights and Market Forecasts to 2024
        • Pipeline Assessment and Insights
        • Market Intelligence Review and Insights
        • Epidemiology Overview and Insights
  • Research & Consulting Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsRespiratoryCystic fibrosis
  • Cystic Fibrosis Foundation grants $5 Mn to Armata Pharmaceuticals for CF therapy

    • March 26, 2020
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • KALYDECO in Cystic Fibrosis receives positive CHMP opinion by EMA

    • October 21, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • Positive results from new triple combinations in Cystic Fibrosis, displayed by Vertex

    • October 21, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • Synspira’s drug receives FDA Orphan Designation for Cystic Fibrosis treatment

    • October 16, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • FDA Approves ORKAMBI in Cystic Fibrosis for Children Ages 2-5 Years

    • August 13, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • Boehringer Ingelheim to Develop novel Gene Therapy for Cystic Fibrosis

    • August 7, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • Kalydeco (ivacaftor) Data Demonstrates Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of Cystic Fibrosis

    • June 7, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
  • Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

    • April 30, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
Newsletter
Recent Posts
  • COPD- How to Manage the disease
  • Prognosis of Epilepsy- Disease definition, Mortality, Relapse risks explained
  • Diagnosing Alzheimer’s disease through symptoms
  • Diet Sources to help prevent Multiple Sclerosis (MS) relapses
  • Symptoms & Treatment For Cystic Fibrosis disease

Contact Us

   enquiry@pharmascroll.com
   +91 977 686 8067
   First Office, 2nd Floor, Plot No:14,
Behind Dena Bank, Madhapur,
Hyderabad, Telangana 500081
Contact Name: Bhawna Gupta

Recent Tweets

  • Bristol Myers Squibb acquires #MyoKardia, for $13.1 billion, along with its #cardiovascular disease portfolio, incl… https://t.co/TVeZl10xsX105 days ago
  • #Roche acquires #Inflazome, along with its entire portfolio comprising of clinical and preclinical orall #NLRP3 inh… https://t.co/BpQRA323cT119 days ago

Recent Posts

  • COPD- How to Manage the disease
  • Prognosis of Epilepsy- Disease definition, Mortality, Relapse risks explained
  • Diagnosing Alzheimer’s disease through symptoms

News Letter

© 2021 Copyright. All rights reserved

Catalyzed by

SPEAK TO AN EXPERT